icon covid

At-Home COVID-19
Nasal Swab Test

FDA-EUA Authorized

  • Self-Administer At-Home
    or at a Doctor’s Office
  • Results in 30 Minutes

24 tests
per box

How It Works

svg ico step1

Step 1: Request Test Kits

Order tests in bulk for your patients. You charge your patients via Cash, HSA, or FSA for the tests and are responsible for getting the test to your patient.

svg ico step2

Step 2: Register Your Patient’s Test Kit

You or your patient registers the kit with their personal information.

icon swab test time na

Step 3: Patients Collect Their Samples

The patient takes the test.

svg ico step4

Step 4: Receives Results

Wait 30 minutes for the results to appear on your Lucira device.

FDA Emergency Use Authorized
At-Home COVID-19 Nasal Swab Test

The Lucira COVID-19 All-In-One Test Kit is a single-use test kit intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. This test is authorized for prescription home use with self-collecting nasal swab samples in individuals aged 14 and older who are suspected of COVID-19 by their healthcare provider.

This test is also authorized for use in Point of Care settings for individuals aged 14 and older, and in individuals aged 13 and under when the specimen is collected by a healthcare provider.

Collection Method:
Nasal Swab

Results Displayed on Device In:
30 minutes

FDA Emergency Use Authorization
https://www.fda.gov/media/143810/download

Contact an expert at 1health to help set up an account.

You will then be able to place purchase orders for your tests.

FDA Authorization

This test has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories. This test has not been FDA cleared or approved. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.